CagY-dependent regulation of type IV secretion in *Helicobacter pylori* is associated with alterations in integrin binding

Emma C. Skoog\(^5\), Vasilios A. Morikis\(^3\), Miriam E. Martin\(^4\), Greg A. Foster\(^3\), Lucy P. Cai\(^5\), Lori M. Hansen\(^5\), Beibei Li\(^5, 6\), Jennifer A. Gaddy\(^7\), Scott I. Simon\(^3\), and Jay V. Solnick\(^{1, 2, 5}\)

\(^1\)Department of Medicine  
\(^2\)Department of Microbiology & Immunology  
\(^3\)Department of Biomedical Engineering  
\(^4\)Department of Microbiology and Molecular Genetics  
\(^5\)Center for Comparative Medicine  
University of California, Davis School of Medicine  
Davis, CA 95616 USA

\(^6\)Shanghai Veterinary Research Institute  
Chinese Academy of Agricultural Science  
Shanghai 200241, P. R. China

\(^7\)Department of Veterans Affairs  
Tennessee Valley Healthcare Systems  
Department of Medicine  
Vanderbilt University Medical Center  
Nashville, TN 37212 USA

Running title: Modulation of *H. pylori* T4SS by CagY-dependent alteration in integrin binding

Correspondence: Jay V. Solnick, Center for Comparative Medicine, University of California, Davis, Davis, CA 95616 USA, jvsolnick@ucdavis.edu, (530) 752-1333 (phone), (530) 752-7914 (fax)

Word count abstract: 236

Word count text: 5842 (intro, results, discussion and methods)
ABSTRACT

Strains of *Helicobacter pylori* that cause ulcer or gastric cancer typically express a type IV secretion system (T4SS) encoded by the *cag* pathogenicity island (PAI). CagY is an ortholog of *VirB10* that, unlike other *VirB10* orthologs, has a large middle repeat region (MRR) with extensive repetitive sequence motifs, which undergo CD4+ T cell-dependent recombination during infection of mice. Recombination in the CagY MRR reduces T4SS function, diminishes the host inflammatory response, and enables the bacteria to colonize at a higher density. Since CagY is known to bind human α5β1 integrin, we tested the hypothesis that recombination in the CagY MRR regulates T4SS function by modulating binding to α5β1 integrin. Using a cell-free microfluidic assay, we found that *H. pylori* binding to α5β1 integrin under shear flow is dependent on the CagY MRR, but independent of the presence of the T4SS pili, which are only formed when *H. pylori* is in contact with host cells. Similarly, expression of CagY in the absence of other T4SS genes was necessary and sufficient for whole bacterial cell binding to α5β1 integrin. Bacteria with variant *cagY* alleles that reduced T4SS function showed comparable reduction in binding to α5β1 integrin, though CagY was still expressed on the bacterial surface. We speculate that *cagY*-dependent modulation of *H. pylori* T4SS function is mediated by alterations in binding to α5β1 integrin, which in turn regulates the host inflammatory response so as to maximize persistent infection.
Infection with *H. pylori* can cause peptic ulcers, and is the most important risk factor for gastric cancer, the third most common cause of cancer death worldwide. The major *H. pylori* virulence factor that determines whether infection causes disease or asymptomatic colonization is the type IV secretion system (T4SS), a sort of molecular syringe that injects bacterial products into gastric epithelial cells and alters host cell physiology. We previously showed that recombination in CagY, an essential T4SS component, modulates the function of the T4SS. Here we found that these recombination events produce parallel changes in specific binding to α5β1 integrin, a host cell receptor that is essential for T4SS-dependent translocation of bacterial effectors. We propose that CagY-dependent binding to α5β1 integrin acts like a molecular rheostat that alters T4SS function and modulates the host immune response to promote persistent infection.
Helicobacter pylori infection most often causes only asymptomatic gastritis, but is considered an important human pathogen because it is the major risk factor for development of peptic ulcer disease and gastric adenocarcinoma (1), the third most common cause of cancer death. On the other hand, H. pylori infection may also have beneficial effects, particularly prevention of chronic diseases that have increased in frequency in developed countries as the prevalence of H. pylori has declined (2). The bacterial virulence factor most strongly associated with the outcome of H. pylori infection is the cag pathogenicity island (cagPAI), a ~40 kb DNA segment that encodes a type IV secretion system (T4SS). When H. pylori comes in contact with the gastric epithelium, it assembles the T4SS pilus (3), through which it injects the CagA oncoprotein into host cells (4). Other T4SS-dependent effectors have also been identified, including DNA (5), peptidoglycan (6) and heptose-1,7-bisphosphate, a metabolic precursor in lipopolysaccharide biosynthesis (7-9). Together, T4SS injection of effector molecules results in complex changes in host cell physiology that include cytoskeletal rearrangements, disruption of tight junctions, loss in cell polarity, and production of interleukin 8 (IL-8) and other proinflammatory cytokines (4, 10).

Host cell expression of β1 integrins is required for T4SS-dependent translocation of CagA (11, 12), and presumably other effectors as well. Four cagPAI proteins essential for T4SS function have been found to bind β1 integrins, though the details are unclear and some reports are contradictory. The first to be described was CagL, an RGD-dependent ligand for α5β1 integrin that presumably mimics fibronectin, an intrinsic host integrin ligand (11). An RGD helper motif in CagL (FEANE) may also be important (13). However, other studies have failed to demonstrate CagL binding to β1 integrins (12), have yielded discrepant results about the role of CagL polymorphisms (14-16), or have identified completely different integrin binding partners, including αvβ5 and αvβ8 (17). CagA, CagI and CagY have also been shown to bind β1 integrin using yeast two hybrid, immunoprecipitation, and flow cytometry approaches (12). However, H. pylori infection may also have beneficial effects, particularly...
pylori binding to integrins has only occasionally been performed with intact bacterial cells (12, 18), and the role of the cagPAI-encoded proteins for integrin binding has not yet been examined in the context of a fully assembled T4SS.

It has long been known that passage of H. pylori in mice results in loss of T4SS function (19, 20). We previously demonstrated that this is typically a result of recombination events in cagY (21), a virB10 ortholog that contains in its middle repeat region (MRR) an extraordinary series of direct DNA repeats that are predicted to encode in-frame insertions or deletions in a surface-exposed region of the protein (22). Recombination events in the cagY MRR lead to expression of an alternative CagY allele that can modulate T4SS function, including induction of IL-8 and translocation of CagA (21). This modulation can occur in a graded fashion, and cause both gain and loss of T4SS function (21). More recently, we demonstrated that IFN\(\gamma\) and CD4+ T cells are essential for cagY-mediated loss of T4SS function, which can rescue colonization in IL10/-/- mice that have an exaggerated inflammatory response to H. pylori infection (23). Together, these results suggest that cagY recombination serves as an immune sensitive molecular rheostat that “tunes” the host inflammatory response so as to maintain persistent infection.

Here we examined the mechanism by which recombination in cagY alters T4SS function. Since CagY forms the spokes of a T4SS core complex, together with CagX, CagM, CagT and Cag3 (24, 25), one possibility is that changes in the MRR alter T4SS function by modifying essential protein-protein interactions, or changing the pore through which effectors must travel. Alternatively, since CagY recombination occurs in the MRR, which is predicted to extend extracellularly, allelic variation in CagY might alter integrin binding. At first glance this seemed unlikely since there are multiple cagPAI proteins that bind integrins. Surprisingly, our results demonstrate that indeed recombination in the CagY MRR alters binding to \(\beta_1\) integrin, which in turn modulates T4SS function. Moreover, the CagY MRR is expressed on the bacterial surface even in the absence of a T4SS pilus. We propose that CagY is a bifunctional protein...
that contains a VirB10 domain that is an essential part of a complete T4SS structure, and an MRR region that mediates close contact to the host cell and modulates T4SS function.
RESULTS

_H. pylori_ binds to α5β1 integrin in a host cell-free assay

Previous studies analyzed binding of _H. pylori_ to β1 integrins by protein-protein interaction assays, protein to host cell binding, or bacterial co-localization to β1 integrin on host cells _in vitro_ (11, 12). To demonstrate binding of intact live _H. pylori_ to β1 integrin, we developed a microfluidic assay in which human recombinant α5β1 integrin was coated on glass cover slips, which served as the substrate of a flow channel (Fig 1A). Fluorescently stained bacteria were flowed through the channel at a defined shear stress (~1 dyne/cm²), microscopic images were recorded, and immobilized fluorescent bacteria were counted. To validate the microfluidic assay, we first analyzed binding of _Escherichia coli_ expressing _Yersinia_ invasin, a well-characterized β1 integrin ligand (26). _Yersinia_ InvA was expressed in _E. coli_ after IPTG stimulation (Fig S1A) and was presented on the bacterial cell surface (Fig 1B). _E. coli_ harboring the plasmid vector alone served as a negative control. _E. coli_ expressing InvA and fluorescently stained with either DiO or DiD showed markedly increased binding to α5β1 compared to control _E. coli_ with vector alone (Fig 1C). Similar results were obtained when InvA and control strains were mixed 1:1 and analyzed simultaneously, which permitted direct comparison in the same flow channel, and limited variability that might otherwise arise from differences in integrin density or flow disturbances on glass coverslips (Fig S1B).

Fluorescently stained _H. pylori_ was also readily visualized adherent to α5β1 integrin (Fig 1D). _H. pylori_ strains J166 and PMSS1 both attached to α5β1 integrin in a concentration-dependent manner and reached saturation at an optical density (OD₆₀₀) of 0.8 (Fig 2A). This correlates with approximately 4x10⁸ bacterial cells per ml and was used for all subsequent experiments. Binding was blocked by pre-incubating the integrin-coated cover slips with P5D2 anti-β1 antibody, which sterically inhibits integrin-dependent binding (Fig 2B). Allosterically stabilizing the α5β1 integrin in the low affinity conformation by pre-incubation with SG19 antibody decreased _H. pylori_-integrin binding, while the TS2/16 antibody that locks α5β1 in the high affinity
conformation yielded binding similar to that of an isotype control, indicating that the majority of derivatized α5β1 is active (Fig 2B). This was also supported by the observation that pretreatment of the microfluidic channels with Mn2+ to lock α5β1 integrin in the high affinity state yielded *H. pylori* adherence similar to that with the TS2/16 antibody and the isotype control (Fig 2B). Adherence to α5β1 integrin was greater than to α4β1 and αLβ2 (Fig 2C). Thus, live whole cell *H. pylori* binds specifically and in a conformation dependent manner to α5β1 integrin.

**H. pylori adherence to α5β1 integrin in a host cell-free assay is dependent on CagY**

To determine if the *cag*PAI, or any of the putative integrin binding partners (CagA, CagI, CagL or CagY), are responsible for α5β1 integrin binding of intact *H. pylori*, we compared deletion mutants of *H. pylori* J166 to the wild type (WT) control. The number of adherent mutant and WT *H. pylori* per field of view was determined, and the results were analyzed as the percent adherence of the mutant compared to WT. Initial control experiments demonstrated that WT and selected mutant strains stained with similar efficiency with both dyes (Fig S2A), and that adhesion was independent of the dye and was similar whether strains were analyzed individually or competitively (Fig S2B). Adherence to α5β1 integrin was markedly reduced by deletion of the entire *cag*PAI (Δ*cag*PAI), but not by deletion of *cagE* (Δ*cagE*) or cagI/L (Δ cagI/L) (Fig 2D). Deletion of *cagA* (Δ*cagA*) produced a small reduction in adherence to α5β1 integrin but the difference was not statistically significant (P=0.25). In contrast, integrin adherence by the *cagY* deletion mutant (Δ*cagY*, shown schematically in Fig 3) was significantly reduced to a level similar to Δ*cag*PAI (Fig 2D). Blocking by treatment with anti-β1 antibody demonstrated β1-specific binding in Δ*cagA*, Δ*cagI/L*, and Δ*cagE* mutants (Fig 2E), which all produced CagY as demonstrated by immunoblot (Fig S3A). Δ*cagY* showed only residual adherence that was not β1-specific (Fig 2E). Together, these results demonstrate that in this host cell-free system, adhesion of *H. pylori* to α5β1 integrin under physiological levels of shear stress is mediated predominantly by CagY.
CagY-mediated integrin binding is independent of the T4SS pilus

\textit{H. pylori} T4SS pilus formation is thought to require host cell contact (27), though this has never been formally demonstrated. Since \textit{H. pylori} attachment to integrin in the flow channel occurs in the absence of host cells, this suggests that \textit{H. pylori} can bind to \(\alpha_5\beta_1\) integrin independent of the T4SS pilus. To examine this further, we used field emission scanning electron microscopy (FEG-SEM) to image the T4SS pili in \textit{H. pylori} WT and \(\Delta\text{cagPAI}\), co-cultured with or without AGS gastric epithelial cells. Numerous pili were observed on WT \textit{H. pylori} J166, but only in the presence of AGS cells (Fig 4). As expected, no pili were detected on \textit{H. pylori} \(\Delta\text{cagPAI}\). The same results were found for \textit{H. pylori} PMSS1 WT and \(\Delta\text{cagPAI}\) (Fig S4).

Culture of \textit{H. pylori} together with \(\alpha_5\beta_1\) integrin also failed to induce pilus formation (data not shown). Therefore, under shear flow in this cell-free system, CagY-mediated binding to \(\alpha_5\beta_1\) integrin does not require formation of the T4SS pilus. To further demonstrate that CagY is sufficient for integrin binding in the absence of the T4SS pilus, all of the PAI genes were deleted except \textit{cagX} and \textit{cagY}, which are transcribed as an operon from a putative promoter located in \textit{cag9}, upstream of \textit{cagX} (28, 29). This mutant, designated \textit{cagXY}, is shown schematically in Fig 3 compared to J166 WT and \(\Delta\text{cagY}\). J166 \textit{cagXY} expresses CagY on the bacterial surface (Fig 5A,C) but fails to induce a robust IL-8 response in AGS cells due to the lack of a T4SS (Fig S5).

In the flow channel \(\alpha_5\beta_1\) integrin binding assay, J166 \textit{cagXY} binds at a level similar to J166 WT (Fig 5E). To exclude a role for CagX, we deleted all \textit{cagPAI} genes and stitched \textit{cagY} directly to the promoter in \textit{cag9}, creating J166 \textit{cagY}. Similar to J166 \textit{cagXY}, J166 \textit{cagY} fails to induce IL-8 (Fig S5), but expresses CagY and binds to \(\alpha_5\beta_1\) integrin similarly to J166 WT (Fig 5B,D and F).

Together these results suggest that in this assay, \textit{H. pylori} binds to \(\alpha_5\beta_1\) integrin predominantly via a CagY-dependent mechanism, but independently of T4SS pilus formation. This conclusion is also supported by the observation that integrin binding in J166 \(\Delta\text{cagI/L}\) and \(\Delta\text{cagE}\), which do not form a T4SS pilus (27), is similar to WT (Fig 2D).
The CagY MRR is necessary for integrin binding

The topography of CagY in the bacterial cell is poorly understood. Proteomic studies suggest that it may be located in the cytoplasmic membrane, or perhaps span the inner and outer membranes [18], similar to what has been demonstrated for the *Escherichia coli* VirB10 (30). However, CagY is much larger than other VirB10 orthologs, and includes two membrane spanning domains that flank the MRR, which previous studies suggested may be localized to the bacterial surface (31). Surface localization is also apparent in deletion mutants of *cagA*, *cagI/L* and *cagE* (Fig S3B), and in J166 *cagXY* (Fig 5A and S3C) and J166 *cagY* (Fig 5D), which do not make a T4SS pilus. We next constructed an unmarked in-frame deletion of the MRR (designated J166Δ*cagY* MRR), which is shown schematically in Fig 3. J166Δ*cagY* MRR does not induce IL-8 (Fig S5) or bind α5β1 integrin in the flow channel (Fig 5E), and, as expected, shows no surface localization of CagY using antibody directed to the MRR (Fig 5C). However, J166Δ*cagY* MRR has an in-frame deletion and produces CagY that can be detected with antibody to the VirB10 portion of CagY (Fig 5A). Together, these results suggest that the *H. pylori* CagY MRR is expressed on the bacterial surface, is required for the binding of α5β1 integrin in a T4SS-independent manner, and is essential for T4SS function.

Variation in the motif structure of the CagY MRR alters binding to α5β1 integrin and T4SS function.

We previously demonstrated, using mouse and non-human primate models, that recombination in the *cagY* MRR regulates T4SS function (21, 23), though the mechanism is unknown. Since we have now shown that the MRR is also required to bind α5β1 integrin in the flow channel, we hypothesized that recombination in *cagY* modulates T4SS function by altering the efficiency of *H. pylori* adhesion to α5β1 integrin. To test this hypothesis, we compared IL-8 induction to integrin adhesion, using three groups of *H. pylori* strains, each with several isogenic
variants bearing unique \textit{cagY} alleles that were previously documented to confer changes in IL-8 induction. First, we examined four isogenic \textit{H. pylori} J166 strains bearing different \textit{cagY} alleles, which arose naturally during infection of mice and were transformed into the WT parent strain (21). All four strains express an unmarked CagY that differs only in the motif structure of the MRR (Fig 6A). Two of the strains induce IL-8 and translocate CagA similarly to WT J166, and two have a non-functional T4SS (21). Consistent with our hypothesis, changes in the J166 CagY MRR that reduced IL-8 also showed a marked and commensurate reduction in adhesion to $\alpha_5\beta_1$ integrin (Fig 6B). Parallel experiments with isogenic strains of \textit{H. pylori} PMSS1 bearing a unique CagY MRR that altered T4SS function (23) showed similar results (Figs 6C and 6D). Finally, we examined the relationship between induction of IL-8 and integrin binding in paired clonal \textit{H. pylori} isolates recovered from a human patient over a period of 7.4 years (KUS13A and KUS13B), and which differed in the CagY MRR and in T4SS function (23). Again we found that MRR-dependent adhesion of each \textit{H. pylori} isolate to $\alpha_5\beta_1$ integrin was in most cases commensurate with the level of IL-8 induction (Fig 6E and 6F). Together these results suggest that recombination in \textit{cagY} modulates T4SS function by altering \textit{H. pylori} attachment to $\alpha_5\beta_1$ integrin.

\textbf{Variant CagY amino acid motifs that differ in integrin binding and T4SS function are expressed on the bacterial surface}

Recombination of \textit{cagY} could modulate integrin binding by changing its amino acid motif structure, but it might also change its level of expression or surface localization. Although in some strains the level of CagY expression appears decreased (e.g. Fig 6A, strain 3), this likely reflects a marked reduction in size of the MRR and reduced antibody recognition. We detected no relationship between MRR expression on western blot and either \textit{H. pylori} adhesion to integrin or induction of IL-8 (Fig 6). CagY MRR was expressed on the bacterial surface in isogenic \textit{H. pylori} PMSS1 strains that differed only in their MRR, and also showed no
relationship to T4SS function or integrin binding (Fig 7A). Analysis of fluorescence intensity normalized to DAPI staining demonstrated quantitatively that CagY was expressed on the bacterial surface at similar levels, with no detection in the negative control (Fig 7B). Quantitation of expression on the bacterial surface of isogenic \textit{cag}PAI mutants of J166 similarly showed no relationship to T4SS function or integrin binding, though all MRR variants showed reduced expression (Fig S3D), perhaps related to the reduction in number of MRR motifs. These results suggest that changes in the motif structure of CagY on the bacterial surface modulate T4SS function by altering bacterial adhesion to $\alpha_5\beta_1$ integrin, rather than altering surface presentation of CagY.
DISCUSSION

*H. pylori* persistence in the gastric mucosa is often attributed to evasion of the innate and adaptive immune response, including antimicrobial peptides (32), toll like receptor signaling (33, 34), and T cell proliferation (35, 36), as well as promotion of a regulatory T cell response (37). However, the very presence in most strains of the *cag*PAI, which promotes the host immune response (38, 39), and the uniform occurrence of gastritis in infected patients, suggest the possibility that the host inflammatory response may at the same time actually promote *H. pylori* colonization, a concept that has recently been elegantly demonstrated for several enteric pathogens (40). This is supported by observations of functional antagonism between some *H. pylori* virulence factors such as the CagA oncoprotein and the VacA cytotoxin (41, 42), and by recent evidence that CagA-dependent inflammation may be important for acquisition of essential nutrients such as iron (43, 44) and zinc (45). This more nuanced view of the relationship between *H. pylori* and the host immune response suggests that the overarching strategy used by *H. pylori* to persist in the stomach might be better characterized as immune regulation rather than simply immune evasion.

CagY is an essential component of the *H. pylori* T4SS that may be well-suited to serve this immune regulatory function. The *cagY* gene has in its middle repeat region (MRR) a series of direct DNA repeats that *in silico* predict in-frame recombination events. Recombination in the *cagY* MRR is in fact common, since variants can be readily detected *in vitro*, though it remains possible that the frequency is increased in response to unknown host signals. We previously showed that *cagY* recombination *in vivo* yields a library of insertions and deletions in the MRR, which maintain CagY expression but frequently alter T4SS function (21). CagY-dependent modulation of T4SS function is graded—more like a rheostat than a switch—and can yield variants that confer both gain and loss of function in vivo (21, 23). Adoptive transfer and knockout mouse experiments demonstrate that development of variant *cagY* alleles requires a CD4+ T cell- and IFNγ-dependent immune response (23). Thus, *cagY* recombination can
modulate T4SS function and may be a bacterial strategy to both up- and down-regulate the host immune response to promote persistent infection.

Here we addressed the mechanism by which recombination in the MRR alters T4SS function. Since CagY is a ligand for $\alpha_5\beta_1$ integrin, which is essential for T4SS function, we hypothesized that changes in the amino acid motif structure from recombination in the MRR might alter integrin binding and modulate T4SS function. Analysis of whole bacterial cells in a microfluidic assay demonstrated CagY-dependent and integrin conformation-specific binding to $\alpha_5\beta_1$, which correlated closely with T4SS function in isogenic variants that differed only in the MRR region of CagY. This binding was independent of the T4SS pilus, which was not formed under these cell-free conditions, though the MRR was expressed on the bacterial surface as described previously (31). Moreover, we could detect the MRR on the bacterial surface even when the entire cagPAI was deleted except for cagY and the upstream promoter. Binding to $\alpha_5\beta_1$ integrin was not dependent upon CagA, CagE, or CagL, which was originally identified as the ligand for $\alpha_5\beta_1$ integrin (11). While CagL is clearly essential for T4SS function, more recent studies have suggested that it binds $\alpha_\text{V}\beta_6$ and $\alpha_\text{V}\beta_8$ integrin and not $\alpha_5\beta_1$ (17). The results from yeast two-hybrid studies (12) also identified CagI as a $\beta_1$ integrin binding partner, which we could not confirm in whole bacterial cells.

Previous studies have found that the VirB10 ortholog at the C-terminus of CagY bound to $\alpha_5\beta_1$ integrin, but not the MRR region. However, these studies examined protein-protein interactions by yeast two-hybrid and immunoprecipitation or by surface plasmon resonance (12, 46), which may not reflect binding in a whole bacterial cell. Since the isogenic cagY variants examined here differed only in the MRR, and deletion of the MRR eliminated $\alpha_5\beta_1$ integrin binding, our results suggest that the H. pylori MRR is required for binding to $\alpha_5\beta_1$ integrin in an intact bacterial cell. However, we have not directly examined MRR binding to $\alpha_5\beta_1$ integrin, so the MRR may not itself be an integrin ligand, but instead may modulate binding of the VirB10 domain of CagY. We have been unable to demonstrate CagY-dependent adherence to $\alpha_5\beta_1$
integrin on AGS gastric epithelial cells in our microfluidic assay (data not shown), which may reflect the multiple binding partners, including cagPAI components, as well as HopQ, BabA, SabA, and other outer membrane adhesins (47, 48). Others have also found no difference in binding to AGS cells between WT and ΔcagPAI (12).

The topology of CagY in the bacterial membrane, and the accessibility to the α5β1 integrin, also remain areas of uncertainty. Integrins are generally found in the basolateral compartment, which would not normally be accessible to *H. pylori* on the apical cell surface. However, *H. pylori* binds preferentially at tight junctions in cell culture and in gastric tissue, leading to disruption of the integrity of the epithelial layer (49). Moreover, recent studies suggest that *H. pylori* HtrA, an essential serine protease, cleaves occludin, claudin-8, and E-cadherin, which opens cell-cell junctions and may explain how *H. pylori* could bind integrins in vivo (50-52). *H. pylori* binding to CEACAMs (53, 54) or other yet identified cell receptors may also induce redistribution of integrins from the basolateral to the apical cell surface, making them accessible to CagY. It also remains unclear precisely how CagY is localized in the bacterial cell membrane.

Elegant cryo-electron microscopy studies have demonstrated that the VirB10 orthologue in the *Escherichia coli* plasmid conjugation T4SS forms part of a core complex that spans the inner and outer bacterial membranes (30). However, the topology in *H. pylori* appears different, as recent electron microscopy studies suggest that the core complex is much larger than that in *E. coli*, and is composed of 5 proteins (rather than 3), including CagX, CagY, CagM, CagT, and Cag3 (25).

In conclusion, these studies demonstrate that CagY modulates attachment to α5β1 integrin independently of the T4SS pilus in a manner that depends on the MRR motif structure. It is tempting to speculate that CagY-mediated alteration in integrin binding is also mechanistically linked to T4SS function, since they are strongly correlated (Figure 6). For example, surface expression of an integrin-binding motif may promote intimate epithelial cell contact, which in turn serves as a nucleation signal to promote expression of the T4SS pilus,
further enhancing integrin binding and injection of effector molecules. Such a scenario might entail MRR-dependent integrin signaling, including activation of focal adhesion kinase (FAK) and the Src family kinase, though others have shown that only the extracellular domains of the β₁ integrin are important for CagA translocation (12). On the other hand, it is logically possible that changes in the MRR affect integrin binding and T4SS function independently. Though the details remain to be elucidated, we hypothesize that CagY-dependent binding to α₅β₁ integrin serves as a molecular rheostat that “tunes” the optimal balance between the competing pressures of gastric inflammation, which serves a metabolic function for the bacterium on the one hand, but comes at a cost of exposure to immune pressure, decreased bacterial load, and decreased possibility of transmission to a new host.
MATERIALS AND METHODS

Construction and culture of *E. coli* expressing InvA

Plasmid pRI253 (kindly provided by Ralph Isberg, Tufts University, Boston, MA) contains the *invA* gene from *Yersinia pseudotuberculosis* under the control of a phage T7 RNA polymerase promoter (55). To create a negative control, the *invA* gene was cut out from the plasmid using restriction enzymes EcoRI and HindIII. The recircularized plasmid pRI253ΔinvA and the original plasmid pRI253 were transformed into competent *E. coli* BL21 (Invitrogen) according to the manufacturers' instructions. *E. coli* strains were cultured overnight at 37°C in Luria Bertani (LB) broth supplemented with 5 mg/liter carbenicillin. Overnight cultures were diluted to an OD$_{600}$ of 0.05, cultured for an additional 2-3 h, followed by addition of 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and another 2 h of incubation to induce InvA expression.

*H. pylori* strains and culture conditions

Wild type *H. pylori* strains were cultured on Brucella agar or in Brucella broth (BBL/Becton Dickinson, Sparks, MD) supplemented with 5% heat-inactivated newborn calf serum (Invitrogen, Carlsbad, CA) and antibiotics (trimethoprim, 5 mg/liter; vancomycin, 10 mg/liter; polymyxin B, 2.5 IU/liter, amphotericin B, 2.5 mg/liter). *H. pylori* mutant strains were cultured as for wild type, but with the addition of kanamycin (25 mg/liter), chloramphenicol (5 mg/liter), or streptomycin (10 mg/liter) as appropriate (all antibiotics from Sigma). *H. pylori* liquid cultures were grown overnight to an optical density at 600 nm (OD$_{600}$) of approximately 0.3 to 0.4. All *H. pylori* cultures were grown at 37°C under microaerophilic conditions generated by a fixed 5% O$_2$ concentration (Anoxomat, Advanced Instruments, Norwood, MA). A complete list of strains is shown in Table 1.
Construction of *H. pylori* mutants

Six mutants in *H. pylori* J166 were constructed (Table 1). For J166ΔcagA, J166ΔcagI/L and J166ΔcagE, DNA fragments upstream and downstream of the respective gene deletion were PCR amplified using primers (Table S1) with restriction sites that permitted ligation to a kanamycin resistance gene (*aphA*), and insertion into the multiple cloning site of pBluescript (Stratagene, La Jolla, CA). The resulting plasmid was transformed into *E. coli* TOP10 (Invitrogen) according to the manufacturers’ instructions, and transformants were grown overnight on Luria-Bertani (LB) plates containing kanamycin. Resistant colonies were inoculated in selective LB broth and plasmids from the resulting culture were purified with a QIAprep® Spin Miniprep kit (Qiagen). Plasmids were sequenced and digested with appropriate enzymes for verification of correct construction prior to natural transformation of *H. pylori* with kanamycin selection. J166 cagXY was created in a similar fashion, but in two steps, first deleting cag1-6 with a chloramphenicol resistance cassette (*cat*) and selection on chloramphenicol, and then deleting cag9-25 with a kanamycin cassette, leaving only cagX, cagY (and its promoter), and cagA, which in strain J166 is not on the cagPAI (56). J166 cagY was made in a series of 3 steps. First an unmarked deletion of cag1-6 was constructed using contraselection. The region was replaced by a *cat-rpsL* cassette, resulting in streptomycin sensitive (*rpsL* encodes dominant streptomycin sensitivity) and chloramphenicol resistant transformants. Then upstream and downstream fragments were stitched together and the PCR product was used to replace the cassette, leaving an unmarked deletion. Next, cag9-25 were deleted as in the cagXY construct, and replaced with a kanamycin cassette. Finally, contraselection was again used to excise the cagX gene, bringing 313 bp upstream of cagX (putatively containing its promoter) immediately upstream of cagY.
J166ΔcagY<sub>MRR</sub>, with an in-frame markerless deletion of the MRR, was constructed using modifications of contraselection described previously (21). Briefly, the MRR was first replaced by insertion of the cat-<i>rpsL</i> cassette in streptomycin resistant <i>H. pylori</i> J166. Fragments upstream and downstream of the MRR were then each amplified with overlapping primers that permitted stitching of the two products in a second PCR reaction. The stitched product was ligated into pBluescript and used in a second transformation reaction to replace cat-<i>rpsL</i>, with selection on streptomycin. All <i>H. pylori</i> deletion mutants were sequence verified to confirm the correct construction.

**Microfluidic adhesion assay**

Microfluidic adhesion assays were assembled as previously described (57). In brief, 25 mm diameter, #1.5 glass coverslips were piranha etched to remove organic molecules and treated with 1% 3-aminopropyltriethoxysilane to add aminosilane groups. Recombinant human α<sub>4</sub>β<sub>1</sub>, α<sub>5</sub>β<sub>1</sub> or α<sub>L</sub>β<sub>2</sub> integrin (R&D Systems, Minneapolis, MN) was adsorbed at 10 mg/liter concentration overnight at 4°C resulting in approximately 2000 sites/μm<sup>2</sup>. Coverslips were then washed and blocked with Hank’s balanced salt solution with 0.1% human serum albumin. Where indicated, the blocking solution was supplemented with 5 mg/liter of anti-integrin β<sub>1</sub> blocking antibody P5D2 (Abcam, San Francisco, CA), low affinity locking anti-integrin β<sub>1</sub> antibody SG19, high affinity locking anti-integrin β<sub>1</sub> antibody TS2/16 (both from Biolegend, San Diego, CA), isotype control antibody B11/6 (Abcam, San Francisco, CA), or 2 mM MnCl<sub>2</sub> (Mn<sup>2+</sup>) to activate integrin. Custom multi-channel microfluidic device (57) was vacuum sealed, outlets were attached to Exigo pumps to provide the negative pressure necessary to induce shear, and inlet reservoirs were loaded with <i>E. coli</i> or <i>H. pylori</i>. Prior to loading, liquid cultured bacteria were stained at an OD<sub>600</sub> of 0.8 with 2% Vybrant Dil, DiD or DiO Cell-Labeling Solution (Grand Island, NY) in Brucella broth for 20 min at 37°C in the dark. Stained bacteria were washed twice with PBS and then resuspended in Brucella broth to the desired final OD<sub>600</sub>. Competitive binding
assays were performed by mixing differently labeled WT and mutant bacteria at an OD$_{600}$ of 0.4 (total OD$_{600}$ 0.8). Shear was induced at 1 dyne/cm$^2$ for 3 minutes followed by a 3 minute period of no shear incubation to allow attachment. Then shear was increased to 1 dyne/cm$^2$ and 10 second videos were taken along the centerline of the channel in four field of views using an inverted TIRF research microscope (Nikon) equipped with a 60X numerical aperture 1.5 immersion TIRF objective and a 120 W arc lamp to capture epi-fluorescence images with the appropriate filter sets (488 nm for DiO, 510 nm for DiD and 543 nm for Dil). Images were captured using a 16-bit digital complementary metal oxide semiconductor Zyla camera (Andor, Belfast BT12 7AL, UK) connected to a PC (Dell) with NIS Elements imaging software (Nikon, Melville, NY). Images were collected with 2x2 binning at a resolution of 1024 x 1024 at a rate of 2 frames per second. Adherent bacteria were identified by the presence of fluorescence, which was cross-checked with an overlaid brightfield image to eliminate fluorescent noise. Small numbers of bacteria that were unstained (typically ~10%) were not counted. Bacteria that remained stationary or tethered after 10 seconds were counted visually in 3 fields of view, and the results were averaged for each biological replicate. To assess reliability, two observers (one blinded) independently scored adherent bacteria at 488 nm and 543 nm in 9 fields of view that contained competitive binding assays (WT and mutant). Mean similarity for the 18 observations was 0.94, which was calculated as $1-[|O_1 - O_2|/ \frac{1}{2}(O_1 + O_2)]$, where $O_1$ and $O_2$ are the independent scores for the two observers, and a value of 1.0 indicates perfect agreement. Data on integrin binding are representative of at least three biological replicates, which in most cases examined three fields of view in duplicate technical replicates.

**Sequencing of cagY**

The DNA sequences of cagY from *H. pylori* PMSS1 and KUS13A and B were determined using single molecule real-time sequencing (Pacific Biosciences, Menlo Park, CA). Briefly, cagY was amplified as previously described (21) and purified PCR products were
submitted to the DNA Technologies Core at the UC Davis Genome Center. The amplicons were sequenced using a PacBio RSII sequencer, with P6C4 chemistry. Data were analyzed using PacBio’s SMRTportal Analysis 2.3.0. Sequences were deposited in GenBank and are available under accession numbers KY613376 - KY613380. \textit{cagY} sequences of \textit{H. pylori} J166 were previously published (21).

\textbf{Assessment of protein expression by fluorescence microscopy}

Liquid cultures of \textit{H. pylori} or IPTG-induced \textit{E. coli} strains were centrifuged (3,000 $\times$ g, 3 min) and resuspended in blocking buffer (PBS with 1% bovine serum albumin and 0.05% Tween 20) at an OD$_{600}$ of 0.4. Each culture was spotted on to two microscope slides using cytofunnels in a cytospin at 1000 rpm for 15 min. Air dried slides were incubated for 1 h with blocking buffer in a humid chamber followed by 1 h incubation with anti-\textit{H. pylori} CagY MRR antibody (31) diluted 1:1000 or anti-Yersinia invasin antibody (58) diluted 1:5000 in blocking buffer. Slides were washed 3 times with PBS and incubated for 1 h in the dark with Alexa Fluor 488 goat anti-rabbit IgG (R37116, Life Technologies) diluted 1:10 in blocking buffer. After further washing, the slides were mounted with FluoroShield with DAPI (Sigma). The slides were stored in the dark and imaged the next day. Photos of all slides were captured with the same exposure time for each antibody and DAPI. Fluorescence intensity was analyzed with the ImageJ software, normalizing the total CagY fluorescence at a given threshold determined by the positive WT sample to the area of the DAPI fluorescence of the bacterial particles.

\textbf{Immunoblots}

Expression of \textit{E. coli} invasin and \textit{H. pylori} CagY MRR were detected by electrophoresis of lysates of liquid cultured bacteria as described previously (21), using polyclonal rabbit antisera to invasin (1:15,000) or CagY MRR (1:10,000) as primary antibodies. Detection of CagY expression in $\Delta$\textit{cagY}$_{\text{MRR}}$, an in-frame deletion of the MRR, was performed using antiserum
from rabbits immunized with the VirB10 portion at the C-terminus of CagY (1:1,000). To
generate the antiserum, DNA encoding the C-terminus of *H. pylori* J166 CagY was PCR
amplified (Table S1), cloned into pGEX-4T-3 vector and transformed into *E. coli* BL21 (both GE
Healthcare). Expression of the GST-fusion protein and preparation of cell extracts was
performed according to manufacturer's instructions. The GST-fusion protein was bound to
Glutathione Sepharose 4B (GE Healthcare) in a column and the GST was cleaved off by
thrombin. The eluate was run on a SDS-PAGE, the purified CagY C-terminus protein was cut
out from the gel and was used to generate rabbit antisera according to standard protocols
(Antibodies, Inc, Davis, CA).

**IL-8 ELISA**

IL-8 was measured essentially as described previously (59). Human AGS gastric
adenocarcinoma cells (ATCC, Manassas, VA) were grown in RPMI 1640 supplemented with
10% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin at 5% CO₂, 37°C.
All antibiotics were excluded from the growth media 24 h prior to *H. pylori* co-culture.
Approximately 5x10⁵ human AGS gastric adenocarcinoma cells were seeded in six well plates
with 1.8 ml RPMI/10% fetal bovine serum, incubated overnight, and then co-cultured with
bacteria diluted in 200 μl Brucella broth to give an MOI of 100:1. Brucella broth with no bacteria
served as a baseline control. Supernatants were harvested after 20-22 hours of culture (37°C,
5% CO₂), stored at -80°C, and then diluted 1:8 prior to IL-8 assay by ELISA (Invitrogen,
Camarillo, CA) performed according to the manufacturer's protocol. WT *H. pylori* J166 or
PMSS1 and its isogenic *cagY* deletion were included on every plate as positive and negative
controls, respectively. IL-8 values were normalized to WT *H. pylori* determined concurrently.

**High resolution field-emission gun scanning electron microscopy analyses**
Bacteria were cultured alone or with AGS cells for 4 hrs at an MOI of 100:1. Bacteria were prepared for scanning electron microscopy as previously described (27, 60). Briefly, samples were cultured on poly-L-lysine coated glass coverslips, and fixed for 1 hour with 2.0% paraformaldehyde/2.5% gluteraldehyde in 0.05 M sodium cacodylate buffer. Cells were washed three times in 0.05 M sodium cacodylate buffer before secondary fixation with 0.1% osmium tetroxide for 15 minutes. Three additional 0.05 M sodium cacodylate buffer washes were performed before subjecting the samples to sequential ethanol dehydration. Cells were dried at the critical point and carbon-coated before imaging with an FEI Quanta 250 FEG-SEM. Pili were enumerated in a blinded fashion using ImageJ software.

**Statistical analysis**

Data are reported as mean ± SEM. Multiple groups were compared using ANOVA, with Tukey’s or Bonferroni’s post hoc test, or with Dunnett’s post hoc test when compared only to WT. Two group comparisons were performed using Student’s $t$ test. All analyses were carried out using GraphPad Prism 5.01 for Windows (GraphPad Software, San Diego, CA). A P-value <0.05 was considered statistically significant.
This work was supported by grants from the National Institutes of Health to SS (AI047294) and to JS (AI108713). VM was supported by National Institutes of Health T32 training grant (AI060555) to JS. JG was supported by the Department of Veterans Affairs Office of Medical Research Career Development Award (IK2BX001701). Core Services, including use of the Cell Imaging Shared Resource were performed through the Vanderbilt University Digestive Disease Research Center supported by National Institutes of Health grant P30DK058404. BL was supported by National Natural Science Foundation of China (31672606). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
ACKNOWLEDGEMENTS

We thank Jordan Feeney, UC Davis, CA, for drawing assistance with Figure 1A, Ralph Isberg, Tufts University, Boston, MA, for providing pRI253 plasmid and Virginia Miller, University of North Carolina, Chapel Hill, NC, for providing anti-invasin antibody.
REFERENCES

1. Wroblewski LE, Peek RM, Jr., Wilson KT. 2010. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 23:713-39.

2. Blaser MJ, Falkow S. 2009. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 7:887-94.

3. Johnson EM, Gaddy JA, Voss BJ, Hennig EE, Cover TL. 2014. Genes required for assembly of pili associated with the Helicobacter pylori cag type IV secretion system. Infect Immun 82:3457-70.

4. Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R. 2000. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287:1497-500.

5. Varga MG, Shaffer CL, Sierra JC, Suarez G, Piazuelo MB, Whitaker ME, Romero-Gallo J, Krishna US, Delgado A, Gomez MA, Good JA, Almqvist F, Skaar EP, Correa P, Wilson KT, Hadjifrangiskou M, Peek RM. 2016. Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system. Oncogene 10.1038/onc.2016.158.

6. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Memet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL. 2004. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5:1166-74.

7. Gall A, Gaudet RG, Gray-Owen SD, Salama NR. 2017. TIFA Signaling in Gastric Epithelial Cells Initiates the cag Type 4 Secretion System-Dependent Innate Immune Response to Helicobacter pylori Infection. MBio 8. 10.1128/mBio.01168-17

8. Zimmermann S, Pfannkuch L, Al-Zeer MA, Bartfeld S, Koch M, Liu J, Rechner C, Soerensen M, Sokolova O, Zamyatina A, Kosma P, Maurer AP, Glowinski F, Pleissner KP, Schmid M, Brinkmann V, Karlas A, Naumann M, Rother M, Machuy N, Meyer TF.
2017. ALPK1- and TIFA-Dependent Innate Immune Response Triggered by the *Helicobacter pylori* Type IV Secretion System. Cell Rep 20:2384-2395.

9. Stein SC, Faber E, Bats SH, Murillo T, Speidel Y, Coombs N, Josenhans C. 2017. *Helicobacter pylori* modulates host cell responses by CagT4SS-dependent translocation of an intermediate metabolite of LPS inner core heptose biosynthesis. PLoS Pathog 13:e1006514.

10. Censini S, Stein M, Covacci A. 2001. Cellular responses induced after contact with *Helicobacter pylori*. Curr Opin Microbiol 4:41-46.

11. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R, Berger J, Sewald N, Konig W, Backert S. 2007. *Helicobacter* exploits integrin for type IV secretion and kinase activation. Nature 449:862-6.

12. Jimenez-Soto LF, Kutter S, Sewald X, Ertl C, Weiss E, Kapp U, Rohde M, Pirch T, Jung K, Retta SF, Terradot L, Fischer W, Haas R. 2009. *Helicobacter pylori* type IV secretion apparatus exploits beta1 integrin in a novel RGD-independent manner. PLoS Pathog 5:e1000684.

13. Conradi J, Tegtmeyer N, Wozna M, Wissbrock M, Michalek C, Gagell C, Cover TL, Frank R, Sewald N, Backert S. 2012. An RGD helper sequence in CagL of *Helicobacter pylori* assists in interactions with integrins and injection of CagA. Front Cell Infect Microbiol 2:70.

14. Yeh YC, Chang WL, Yang HB, Cheng HC, Wu JJ, Sheu BS. 2011. *H. pylori* CagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin alpha5beta1 related with gastric carcinogenesis. Mol Carcinog 50:751-9.

15. Tegtmeyer N, Lind J, Schmid B, Backert S. 2014. *Helicobacter pylori* CagL Y58/E59 mutation turns-off type IV secretion-dependent delivery of CagA into host cells. PLoS One 9:e97782.
16. Tafreshi M, Zwickel N, Gorrell RJ, Kwok T. 2015. Preservation of *Helicobacter pylori* CagA Translocation and Host Cell Proinflammatory Responses in the Face of CagL Hypervariability at Amino Acid Residues 58/59. PLoS One 10:e0133531.

17. Barden S, Niemann HH. 2015. Adhesion of several cell lines to *Helicobacter pylori* CagL is mediated by integrin alphaVbeta6 via an RGDLXXL motif. J Mol Biol 427:1304-15.

18. Sause WE, Keilberg D, Aboulhouda S, Ottemann KM. 2016. The *Helicobacter pylori* autotransporter ImaA tempers the bacterium’s interaction with alpha5beta1 integrin. Infect Immun 10.1128/iai.00450-16.

19. Philpott DJ, Belaid D, Troubadour P, Thiberge JM, Tankovic J, Labigne A, Ferrero RL. 2002. Reduced activation of inflammatory responses in host cells by mouse-adapted *Helicobacter pylori* isolates. Cell Microbiol 4:285-96.

20. Crabtree JE, Ferrero RL, Kusters JG. 2002. The mouse colonizing *Helicobacter pylori* strain SS1 may lack a functional cag pathogenicity island. Helicobacter 7:139-40; author reply 140-1.

21. Barrozo RM, Cooke CL, Hansen LM, Lam AM, Gaddy JA, Johnson EM, Cariaga TA, Suarez G, Peek RM, Jr., Cover TL, Solnick JV. 2013. Functional plasticity in the type IV secretion system of *Helicobacter pylori*. PLoS Pathog 9:e1003189.

22. Aras RA, Fischer W, Perez-Perez GI, Crosatti M, Ando T, Haas R, Blaser MJ. 2003. Plasticity of repetitive DNA sequences within a bacterial (Type IV) secretion system component. J Exp Med 198:1349-60.

23. Barrozo RM, Hansen LM, Lam AM, Skoog EC, Martin ME, Cai LP, Lin Y, Latoscha A, Suerbaum S, Canfield DR, Solnick JV. 2016. CagY is an Immune-Sensitive Regulator of the *Helicobacter pylori* Type IV Secretion System. Gastroenterology 10.1053/j.gastro.2016.08.014.
24. Kutter S, Buhrdorf R, Haas J, Schneider-Brachert W, Haas R, Fischer W. 2008. Protein subassemblies of the Helicobacter pylori Cag type IV secretion system revealed by localization and interaction studies. J Bacteriol 190:2161-71.

25. Frick-Cheng AE, Pyburn TM, Voss BJ, McDonald WH, Ohi MD, Cover TL. 2016. Molecular and Structural Analysis of the Helicobacter pylori cag Type IV Secretion System Core Complex. MBio 7. 10.1128/mBio.02001-15

26. Isberg RR, Leong JM. 1990. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 60:861-71.

27. Shaffer CL, Gaddy JA, Loh JT, Johnson EM, Hill S, Hennig EE, McClain MS, McDonald WH, Cover TL. 2011. Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLoS Pathog 7:e1002237.

28. Sharma CM, Hoffmann S, Darfeuille F, Reignier J, Findeiss S, Sittka A, Chabas S, Reiche K, Hackermuller J, Reinhardt R, Stadler PF, Vogel J. 2010. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 464:250-5.

29. Ta LH, Hansen LM, Sause WE, Shiva O, Millstein A, Ottemann KM, Castillo AR, Solnick JV. 2012. Conserved transcriptional unit organization of the cag pathogenicity island among Helicobacter pylori strains. Front Cell Infect Microbiol 2:46.

30. Chandran V, Fronzes R, Duquerroy S, Cronin N, Navaza J, Waksman G. 2009. Structure of the outer membrane complex of a type IV secretion system. Nature 462:1011-5.

31. Rohde M, Puls J, Buhrdorf R, Fischer W, Haas R. 2003. A novel sheathed surface organelle of the Helicobacter pylori cag type IV secretion system. Mol Microbiol 49:219-34.
Bauer B, Pang E, Holland C, Kessler M, Bartfeld S, Meyer TF. 2012. The *Helicobacter pylori* virulence effector CagA abrogates human beta-defensin 3 expression via inactivation of EGFR signaling. Cell Host Microbe 11:576-86.

Andersen-Nissen E, Smith KD, Strobe KL, Barrett SL, Cookson BT, Logan SM, Aderem A. 2005. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A 102:9247-52.

Cullen TW, Giles DK, Wolf LN, Ecobichon C, Boneca IG, Trent MS. 2011. *Helicobacter pylori* versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa. PLoS Pathog 7:e1002454.

Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. 2003. *Helicobacter pylori* vacuolating cytotoxin inhibits T lymphocyte activation. Science 301:1099-102.

Sundrud MS, Torres VJ, Unutmaz D, Cover TL. 2004. Inhibition of primary human T cell proliferation by *Helicobacter pylori* vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A 101:7727-32.

Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C, Muller A. 2013. *Helicobacter pylori* gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A 110:3047-52.

Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T, Muller A. 2011. Tolerance rather than immunity protects from *Helicobacter pylori*-induced gastric preneoplasia. Gastroenterology 140:199-209.

Hornsby MJ, Huff JL, Kays RJ, Canfield DR, Bevins CL, Solnick JV. 2008. *Helicobacter pylori* induces an antimicrobial response in rhesus macaques in a *cag* pathogenicity island-dependent manner. Gastroenterology 134:1049-57.

Baumler AJ, Sperandio V. 2016. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535:85-93.
41. Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J, Hibi T. 2012. Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe 12:764-77.

42. Yokoyama K, Higashi H, Ishikawa S, Fujiy Y, Kondo S, Kato H, Azuma T, Wada A, Hirayama T, Aburatani H, Hatakeyama M. 2005. Functional antagonism between Helicobacter pylori CagA and vacuolating toxin VacA in control of the NFAT signaling pathway in gastric epithelial cells. Proc Natl Acad Sci U S A 102:9661-6.

43. Noto JM, Gaddy JA, Lee JY, Piazuelo MB, Friedman DB, Colvin DC, Romero-Gallo J, Suarez G, Loh J, Slaughter JC, Tan S, Morgan DR, Wilson KT, Bravo LE, Correa P, Cover TL, Amieva MR, Peek RM, Jr. 2013. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest 123:479-92.

44. Tan S, Noto JM, Romero-Gallo J, Peek RM, Jr., Amieva MR. 2011. Helicobacter pylori perturbs iron trafficking in the epithelium to grow on the cell surface. PLoS Pathog 7:e1002050.

45. Gaddy JA, Radin JN, Loh JT, Piazuelo MB, Kehl-Fie TE, Delgado AG, Ilca FT, Peek RM, Cover TL, Chazin WJ, Skaar EP, Scott Algood HM. 2014. The host protein calprotectin modulates the Helicobacter pylori cag type IV secretion system via zinc sequestration. PLoS Pathog 10:e1004450.

46. Koelblen T, Berge C, Cherrier MV, Brillet K, Jimenez-Soto L, Ballut L, Takagi J, Montserret R, Rousselle P, Fischer W, Haas R, Fronzes R, Terradot L. 2017. Molecular dissection of protein-protein interactions between integrin alpha5beta1 and the Helicobacter pylori Cag type IV secretion system. FEBS J 284:4143-4157.

47. Aspholm-Hurtig M, Dailide G, Lahmann M, Kalia A, Ilver D, Roche N, Vikstrom S, Sjostrom R, Linden S, Backstrom A, Lundberg C, Arnqvist A, Mahdavi J, Nilsson UJ, Velapatino B, Gilman RH, Gerhard M, Alarcon T, Lopez-Brea M, Nakazawa T, Fox JG,
Correa P, Dominguez-Bello MG, Perez-Perez GI, Blaser MJ, Normark S, Carlstedt I, Oscarson S, Teneberg S, Berg DE, Boren T. 2004. Functional adaptation of BabA, the *H. pylori* ABO blood group antigen binding adhesin. Science 305:519-22.

Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadstrom T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T. 2002. *Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation. Science 297:573-8.

Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. 2003. Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. Science 300:1430-4.

Schmidt TP, Perna AM, Fugmann T, Bohm M, Jan H, Haller S, Gotz C, Tegtmeyer N, Hoy B, Rau TT, Neri D, Backert S, Schneider G, Wessler S. 2016. Identification of E-cadherin signature motifs functioning as cleavage sites for *Helicobacter pylori* HtrA. Sci Rep 6:23264.

Tegtmeyer N, Moodley Y, Yamaoka Y, Pernitzsch SR, Schmidt V, Traverso FR, Schmidt TP, Rad R, Yeoh KG, Bow H, Torres J, Gerhard M, Schneider G, Wessler S, Backert S. 2016. Characterisation of worldwide *Helicobacter pylori* strains reveals genetic conservation and essentiality of serine protease HtrA. Mol Microbiol 99:925-44.

Tegtmeyer N, Wessler S, Necchi V, Rohde M, Harrer A, Rau TT, Asche CI, Boehm M, Loessner H, Figueiredo C, Naumann M, Palmisano R, Solcia E, Ricci V, Backert S. 2017. *Helicobacter pylori* Employ a Unique Basolateral Type IV Secretion Mechanism for CagA Delivery. Cell Host Microbe 22:552-560.e5.

Javaheri A, Kruse T, Moonens K, Mejias-Luque R, Debraekeleer A, Asche CI, Tegtmeyer N, Kalali B, Bach NC, Sieber SA, Hill DJ, Koniger V, Hauck CR, Moskalenko R, Haas R, Busch DH, Klaile E, Slevogt H, Schmidt A, Backert S, Remaut H, Singer BB,
Gerhard M. 2016. *Helicobacter pylori* adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol 2:16189.

Koniger V, Holsten L, Harrison U, Busch B, Loell E, Zhao Q, Bonsor DA, Roth A, Kengmo-Tchoupa A, Smith SL, Mueller S, Sundberg EJ, Zimmermann W, Fischer W, Hauck CR, Haas R. 2016. *Helicobacter pylori* exploits human CEACAMs via HopQ for adherence and translocation of CagA. Nat Microbiol 2:16188.

Isberg RR, Leong JM. 1988. Cultured mammalian cells attach to the invasin protein of *Yersinia pseudotuberculosis*. Proc Natl Acad Sci U S A 85:6682-6.

Linz B, Windsor HM, McGraw JJ, Hansen LM, Gajewski JP, Tomsho LP, Hake CM, Solnick JV, Schuster SC, Marshall BJ. 2014. A mutation burst during the acute phase of *Helicobacter pylori* infection in humans and rhesus macaques. Nat Commun 5:4165.

Dixit N, Yamayoshi I, Nazarian A, Simon SI. 2011. Migrational guidance of neutrophils is mechanotransduced via high-affinity LFA-1 and calcium flux. J Immunol 187:472-81.

Pepe JC, Badger JL, Miller VL. 1994. Growth phase and low pH affect the thermal regulation of the *Yersinia enterocolitica* *inv* gene. Mol Microbiol 11:123-35.

Israel DA, Salama N, Arnold CN, Moss SF, Ando T, Wirth HP, Tham KT, Camorlinga M, Blaser MJ, Falkow S, Peek RM, Jr. 2001. *Helicobacter pylori* strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J Clin Invest 107:611-20.

Haley KP, Blanz EJ, Gaddy JA. 2014. High resolution electron microscopy of the *Helicobacter pylori* Cag type IV secretion system pili produced in varying conditions of iron availability. J Vis Exp10.3791/52122:e52122.

Delahay RM, Balkwill GD, Bunting KA, Edwards W, Atherton JC, Searle MS. 2008. The highly repetitive region of the *Helicobacter pylori* CagY protein comprises tandem arrays of an alpha-helical repeat module. J Mol Biol 377:956-71.
62. Dubois A, Berg DE, Incecik ET, Fiala N, Heman-Ackah LM, Perez-Perez GI, Blaser MJ. 1996. Transient and persistent experimental infection of nonhuman primates with *Helicobacter pylori*: implications for human disease. Infect Immun 64:2885-91.

63. Morelli G, Didelot X, Kusecek B, Schwarz S, Bahlawane C, Falush D, Suerbaum S, Achtman M. 2010. Microevolution of *Helicobacter pylori* during prolonged infection of single hosts and within families. PLoS Genet 6:e1001036.
FIGURE LEGENDS

Fig 1. Microfluidic detection of bacterial adherence to recombinant \( \alpha_5\beta_1 \) integrin. (A) Schematic diagram and photograph of the microfluidic flow cell assembly. (B) Immunofluorescent detection of InvA on the surface of non-permeabilized IPTG-treated \( E. coli \) containing the pRI253 plasmid with or without \( \text{invA} \). (C) Attachment to \( \alpha_5\beta_1 \) integrin of IPTG-treated \( E. coli \). Each strain was used at an OD\( _{600} \) of 0.8, labeled with DiD or DiO and assayed separately. (D) Micrograph of \( H. pylori \) J166 labeled with DiO membrane dye, attached to \( \alpha_5\beta_1 \) integrin in the microfluidic flow cell. Brightfield and fluorescence overlay of the field of view (FOV) demonstrates fluorescent labeling of \( H. pylori \).

Fig 2. \( \alpha_5\beta_1 \) integrin adherence of WT \( H. pylori \) J166 and cagPAI deletion mutants. (A) Adherent \( H. pylori \) J166 and PMSS1 per FOV as a function of bacterial optical cell density at 600 nm (OD\( _{600} \)). (B) Adherent \( H. pylori \) after pre-incubation of flow cells with B11/6 isotype control antibody, P5D2 antibody to sterically inhibit \( \beta_1 \) integrin binding, or antibodies to lock the integrin in the low (SG19) or high (TS2/16) affinity conformation, respectively. Treatment of integrin with Mn\( ^{2+} \) to stabilize the high affinity state produced results similar to treatment with TS2/16 and the B11/6 isotype control antibody. (C) Adherence to \( \alpha_5\beta_1 \), \( \alpha_4\beta_1 \) and \( \alpha_L\beta_2 \) integrins. (D) Adherence to \( \alpha_5\beta_1 \) integrin of J166 WT and deletion mutants, which were fluorescently labeled with DiO and Dil, respectively, mixed in a 1:1 ratio, and enumerated by counting fluorescent bacteria per field of view (FOV). Results are expressed as the ratio of deletion mutant to WT. (E) Steric inhibition with P5D2 antibody (white bars) demonstrated that adherence is integrin-specific. \( \Delta \text{cagY} \) adherence was similar with and without steric inhibition, suggesting that it represents only non-specific background binding. Results are mean (\( \pm \) SEM) of 3 to 5 independent experiments. *\( P<0.05 \), **\( P<0.01 \), ***\( P<0.001 \).
Fig 3. Schematic diagram of the *H. pylori* J166 cagPAI in the WT and selected deletion mutants. In J166ΔcagY, the entire cagY gene is replaced by a cat-rpsL cassette (streptomycin susceptibility and chloramphenicol resistance). ΔcagY_MRR has an unmarked, in-frame deletion of the MRR created by contraselection. In J166 cagXY, cag1-6 is replaced with cat, and cag9-25 is replaced with a kanamycin resistance cassette, starting from after the putative cagY promoter in cag9. J166 cagY has an unmarked deletion of cag1-6 and cagX, while cag9-25 downstream of the cagX/Y promoter in cag9 are replaced with a kanamycin resistance cassette. cagA is intact in all strains since it is not on the cagPAI in J166 (56).

Fig 4. Field emission scanning electron microscopy (FEG-SEM) of *H. pylori* demonstrates that host cell contact is required for T4SS pilus formation. (A) FEG-SEM of *H. pylori* J166 WT and ΔcagPAI cultured with or without AGS cells. Pili are indicated by white arrows. Scale bar, 1 µm. (B) Enumeration of pili per bacterial cell. ***P<0.001, compared with WT.

Fig 5. The CagY middle repeat region (MRR), but not the T4SS pilus, is required to bind α5β1 integrin in a host cell-free system and is expressed on the bacterial surface. (A and B) Immunoblot detection of the CagY MRR and VirB10 region in bacterial lysates. (C and D) Immunofluorescent detection of the CagY MRR on the surface of non-permeabilized *H. pylori*. (E and F) Flow channel competitive adherence to α5β1 integrin. Results are expressed as the ratio of deletion mutant to WT adherence, and represent the mean (± SEM) of at least 3 independent experiments. ***P<0.001

Fig 6. Variation in the amino acid motif structure of the CagY MRR regulates T4SS function by altering α5β1 integrin binding. Western blot detection of the CagY MRR in whole cell bacterial lysates of *H. pylori* J166 (A) or PMSS1 (C) isogenic strains, each bearing unique cagY alleles, or their ΔcagY deletion mutants. The corresponding amino acid structure of the
MRR is shown schematically as a series of A (orange) or B (yellow) motifs, each 31-39 residues, based on DNA sequence analysis as described previously (61). IL-8 induction (white bars) and integrin adhesion (black bars) relative to WT are shown for *H. pylori* J166 (B) and PMSS1 (D) that correspond to strains shown in panels A and C, respectively. (E) Western blot detection and schematic of the CagY MRR (derived as in panels A and C) from KUS13A, KUS13B, and isogenic variants in which *cagY* was deleted (Δ*cagY*) or replaced with that from the variant strain (i.e., KUS13A with *cagY*<sub>13B</sub> or KUS13B with *cagY*<sub>13A</sub>). (F) IL-8 induction (white bars) and integrin adhesion (black bars) relative to WT for the strains shown in panel E. Quantitative results represent the mean (± SEM) of at least 3 independent experiments. *P<0.05, ***P<0.001 for comparison of WT to isogenic *cagY* deletion and variants. Results for IL-8 are adapted from references 20 and 22.

Fig 7. Recombination in *cagY* does not change its surface expression. (A) Immunofluorescent detection of the CagY MRR on the surface of non-permeabilized *H. pylori* PMSS1 with distinct *cagY* alleles from mouse output strains. (B) Quantification of CagY MRR mean fluorescence intensity (MFI) normalized to DAPI. Results are expressed as the percentage ratio of deletion mutant to WT, and represent the mean (± SEM) of 3 independent experiments. *P<0.05, compared to WT.
**SUPPORTING FIGURE LEGENDS**

**S1 Fig. Adherence of invasin expressing *E. coli*.** (A) Immunoblot of *E. coli* with plasmid pRI253 with or without invA, untreated or treated with IPTG to induce InvA expression. Full length InvA is around 100 kDa and the lower bands represent degradation products (55, 58). (B) Attachment to α5β1 integrin in a competitive assay; the two strains of *E. coli* were stained with either DiD or DiO and mixed 1:1 for a total OD\(_{600}\) of 0.8. A parallel dye swap was performed to exclude influence of the dye on the integrin attachment.

**S2 Fig. Fluorophore labeling control experiments.** (A) Percent of cells stained with Dil or DiO ([fluorescently stained cells divided by total cells seen on brightfield] x 100) was determined for *H. pylori* J166 WT, ΔcagPAI, ΔcagY, and isogenic strains expressing functional (ΔcagY[Out1]) or non-functional (ΔcagY[Out3]) cagY alleles. (B) *H. pylori* J166 WT and ΔcagPAI (each at OD\(_{600}\)=0.4) were labeled with Dil or DiO, respectively (left), mixed 1:1, and imaged with a 546 nm (DiI) or 488 nm (DiO) light source. Parallel experiments were performed with a dye swap (middle). WT labeled with Dil was also mixed with WT labeled with DiO (right). Binding to α5β1 integrin was similar whether detected with DiO or Dil fluorescent dyes, and whether in competition with a strain with low or high binding ability. Results for WT measured in a competition setting were also very similar to that when measured individually (compare with Fig 2B). Data represent mean ± SEM of ≥3 experiments.

**S3 Fig. Expression of CagY in wild type and isogenic knockouts of *H. pylori* J166.** (A) Immunoblot of CagY in WT *H. pylori* and isogenic knockouts of cagY, cagA, cagI/L, and cagE. Immunoblot of UreB is shown as a loading control. (B-D) Quantification of whole cell CagY MRR fluorescence signal normalized to DAPI in non-permeabilized WT *H. pylori* and isogenic knockouts or cagY variants. CagY surface expression in strains with MRR motifs that bind α5β1...
integrin and have a functional cagPAI (variants 1 and 2) is similar to that in strains that do not bind integrin and do not have a functional cagPAI (variants 3 and 4), though all are generally lower than J166 WT. Results are expressed as the percentage ratio of deletion mutant to WT, and represent the mean (± SEM) of 3 independent experiments. (MFI=mean fluorescence intensity) *P<0.05, **P<0.01, ***P<0.001 compared to WT.

S4 Fig. Field emission scanning electron microscopy (FEG-SEM) of H. pylori PMSS1. (A) FEG-SEM of H. pylori PMSS1 WT and ΔcagPAI cultured with or without AGS cells. Pili are indicated by white arrows. (B) Enumeration of pili per bacterial cell. ***P<0.001.

S5 Fig. T4SS function in various cagPAI H. pylori J166 mutants. IL-8 induction in AGS cell co-cultured with J166 WT, ΔcagY, cagXY, cagY and ΔcagY_{MRR}. ***P<0.001.

S1 Table. Primers used for PCR.
**Table 1. H. pylori strains**

| Strain                  | Relevant characteristic(s)                     | Antibiotic resistance* | Source (Reference) |
|-------------------------|------------------------------------------------|------------------------|--------------------|
| **E. coli strains**     |                                                |                        |                    |
| BL21 invA +             | E. coli BL21 with plasmid pRI253               | Amp                    | (55)               |
| BL21 invA +             | E. coli BL21 with plasmid pRI253ΔinvA          | Amp                    | this study         |
| **H. pylori wild type strains** |                                              |                        |                    |
| J166                    | Wild type                                      |                        | (62)               |
| PMSS1                   | Wild type                                      |                        | (38)               |
| KUS13A                  | Clinical isolate from patient KUS13            |                        | (63)               |
| KUS13B                  | Isolate from patient KUS13 7.4 yrs after isolate A |                      | (63)               |
| **Deletion mutants**    |                                                |                        |                    |
| J166ΔcagPAI             | Deletion of the entire cagPAI                 | Cm, Km                 | (39)               |
| J166ΔcagA               | J166ΔcagA::aphA                                | Km                     | this study         |
| J166ΔcagI/L             | J166ΔcagI/L::aphA                              | Km                     | this study         |
| J166ΔcagY               | J166 StrΔcagY::cat_rpsL                         | Cm                     | (21)               |
| J166ΔcagE               | J166ΔcagE::aphA                                | Km                     | this study         |
| J166 cagXY              | J166Δcag1-6::cat,Δcag9-25::aphA                | Cm, Km                 | this study         |
| J166 ΔcagYΔMRR          | J166 StrΔcagYΔMRR                              | Str                    | this study         |
| **J166 cagY replacements** |                                              |                        |                    |
| ΔcagY[mOut1]            | J166ΔcagY replaced with cagY from mOut1       | Str                    | (21)               |
| ΔcagY[mOut2]            | J166ΔcagY replaced with cagY from mOut2       | Str                    | (21)               |
| ΔcagY[mOut3]            | J166ΔcagY replaced with cagY from mOut3       | Str                    | (21)               |
| ΔcagY[mOut4]            | J166ΔcagY replaced with cagY from mOut4       | Str                    | (21)               |
| **PMSS1 cagY replacements** |                                              |                        |                    |
| ΔcagY[Out1]             | PMSS1ΔcagY replaced with cagY from Out1       | Str                    | (23)               |
| ΔcagY[Out2]             | PMSS1ΔcagY replaced with cagY from Out2       | Str                    | (23)               |
| ΔcagY[Out3]             | PMSS1ΔcagY replaced with cagY from Out3       | Str                    | (23)               |
| **CagY replacement clinical isolates** |                                              |                        |                    |
| KUS13AΔcagY             | KUS13AΔcagY::cat_rpsL                           | Cm                     | (23)               |
| KUS13BΔcagY             | KUS13BΔcagY::cat_rpsL                           | Cm                     | (23)               |
| KUS13AΔcagY[KUS13B]     | KUS13AΔcagY replaced with cagY from KUS13B   | Str                    | (23)               |
| KUS13BΔcagY[KUS13A]     | KUS13BΔcagY replaced with cagY from KUS13A  | Str                    | (23)               |

*Amp, Ampicillin; Cm, chloramphenicol; Km, kanamycin; Str, streptomycin
With AGS Cells | No AGS Cells

A

WT

ΔcagPAI

B

With AGS Cells | No AGS Cells

H. pylori J166

Pili per cell

***
